Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics Revenue

In the fiscal year ending June 30, 2025, Prescient Therapeutics had annual revenue of 4.36M AUD with 17.35% growth. Prescient Therapeutics had revenue of 3.11M in the half year ending June 30, 2025, with 164.84% growth.

• Revenue: 4.36M
• Revenue Growth: +17.35%
• P/S Ratio: 18.34
• Revenue / Employee: 1.45M
• Employees: 3
• Market Cap: 79.92M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2025	4.36M	644.03K	17.35%
Jun 30, 2024	3.71M	1.28M	52.89%
Jun 30, 2023	2.43M	538.79K	28.52%
Jun 30, 2022	1.89M	703.86K	59.37%
Jun 30, 2021	1.19M	156.14K	15.17%